28th Annual EuroMeeting

The current translation from research to new health interventions offers a wide and growing range of opportunities, generating a rapidly growing number of product development, particularly in small targeted population (orphan medicinal products, other rare disease therapies, paediatric use) and highly innovative products (small molecules, gene therapies, cell therapies, etc). But what triggers these developments? What are the drivers for companies’ decision makers on their investment? The value of new medicines gives high value for unmet needs. Is that fully considered by companies, and if not why? How could we stimulate investment and product developments in areas where there are unmet patient needs? As well as in areas where new products would bring a very high new therapeutic added value or a significantly improved cost effectiveness? Regulators, HTA and payers need to know what is coming up since new treatments bring with them series of new questions on the underlying science, on the delivery of treatment, on the impact on healthcare budget. Would horizon scanning be an appropriate answer and how could we envisage to perform it? Can we make better use of existing incentives and should we consider new incentives, if so which ones?